Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615270 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
A Early Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT07615270: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT07615270 is a Early Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07615270, a Early Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
Interventions
- DRUG Anselamimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615270
The ClinicalTrials.gov registry entry for NCT07615270 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anselamimab is the first listed.
NCT07615270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615270 about?
NCT07615270 is a clinical study titled "A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement". This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
What is the current status of trial NCT07615270?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07615270?
The interventions under investigation include: Anselamimab (DRUG).
Who is sponsoring clinical trial NCT07615270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.